Investment Case Summary
- The 25% discount to last close signals weak negotiating position despite a small raise size.
- 300 million new shares plus 25 million IR shares materially expand the register at sub-cent levels.
- A$900,000 spread across four product lines leaves no obvious lead horse for investors to back.
300 million new shares at 0.3 cents puts the share count under serious pressure
Skin Elements (ASX:SKN) has secured A$900,000 in firm commitments from sophisticated and professional investors, with the placement priced at 0.3 cents per share. That is a 25% discount to the last close of 0.4 cents and a 32.8% discount to the five-day VWAP. For a stock already trading in fractions of a cent, that pricing tells you most of what you need to know about the negotiating position.
The capital will fund existing product programs across ECO Nurture bio stimulant, SuprCuvr disinfectant, Soleo Organics sunscreen and the PapayaActivs therapeutic skincare range. Phoenix Global Investments acted as sole lead manager and will also pick up a 12-month investor relations mandate paid in 25 million escrowed shares.
The announcement landed alongside a fresh board structure. Rod Nicholas was appointed non-executive chairman effective 23 June 2026, with director fees reset to A$48,000 and the chair on A$60,000. The thrift is welcome at this market cap, but it also signals just how tight the cost base needs to run from here.
- Updated
- INSIDER CONVICTION TRADES FY26
The market hasn't noticed yet.
Disclosed by law. Missed by most investors. 129 trades tracked by us.
NO Credit card
- Director buys & sells tracked
- Buy / Hold / Sell verdict on every stock
- Technical analysis included
The 300 million new shares change the structure of the equity story
The raise issues 300 million new shares plus another 25 million to Phoenix for IR services. At a 0.3 cent issue price, this is the kind of placement that almost always leaves a price overhang once escrow restrictions roll off the IR tranche in 12 months.
Our concern is straightforward. When a company has to discount the last traded price by a quarter to clear A$900,000, it is telling the market that conventional working capital channels are not available on better terms. The placement gets done, but at a cost to existing holders that compounds with every subsequent raise at similar levels.
Four product lines, one balance sheet, and the focus problem
The funds are being spread across four distinct programs in disinfectant, agricultural bio stimulant, sunscreen and therapeutic skincare. Each of these sits in a different commercial channel with different customers, regulators and route to market.
We think the question investors should be asking is which of these four actually generates revenue traction inside the next 12 months. A$900,000 does not stretch across four parallel commercial pushes, so management will need to pick winners. The announcement gives no signal on which program gets the lion’s share of the working capital.
The Investors Takeaway for Skin Elements
The balance sheet is patched for now, but at this burn rate and share price, the next conversation about funding is not far away. The board fee cut helps preserve cash, and the new chairman brings a fresh accountability lens, but the real test is commercial. Investors will want to see one of the four product lines generate enough revenue or partnership news to justify a re-rate before the next placement gets priced.
Readers can find our previous coverage including the interview with then-chairman Peter Malone at stocksdownunder, which provides useful context on how the portfolio has evolved. The skeptical read is that the same four-product strategy has been the story for years now, and another small placement at a deep discount does not change the underlying execution challenge.
